Alexandria Pharmaceuticals results, Q2 2024
Net profit, assets, equity and cash flow for Q2 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit78.64 millionEGP · +148.0% vs the same period a year earlier
Total assets1.25 billionEGP · +26.2% vs the same period a year earlier
Shareholders' equity717 millionEGP · +17.6% vs the same period a year earlier
Operating cash flow113 millionEGP · +12.5% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q2 2024 was about 78.64 million EGP, up +148.0% from 31.71 million EGP in Q2 2023.
- Total assets at the end of Q2 2024 were about 1.25 billion EGP, and shareholders' equity about 717 million EGP.
- Operating cash flow for Q2 2024 was positive at 113 million EGP.
Key lines against the same period a year earlier
This periodQ2 2023Change
Net profit78.64 million31.71 million+148.0%
Gross profit-126 million67.59 million−287.1%
Total assets1.25 billion994 million+26.2%
Total liabilities537 million384 million+39.8%
Shareholders' equity717 million610 million+17.6%
Total liabilities and equity1.25 billion994 million+26.2%
Operating cash flow113 million100 million+12.5%
Investing cash flow-5.35 million-13.76 million+61.1%
Financing cash flow-51.09 million-47.49 million−7.6%
Net change in cash56.27 million38.93 million+44.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy